Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Haematological malignancies

891MO - Role of baseline PET SUVmax in predicting early progression in follicular lymphoma (FL): A single-center retrospective analysis

Date

18 Sep 2020

Session

Mini Oral - Haematological malignancies

Topics

Tumour Site

Lymphomas

Presenters

Ayushi Chauhan

Citation

Annals of Oncology (2020) 31 (suppl_4): S590-S598. 10.1016/annonc/annonc261

Authors

A. Chauhan1, B. Dreta2, P.E. Sackstein3, J. Ahn1, B.D. Cheson1

Author affiliations

  • 1 Hematology Oncology, Lombardi Cancer Center Georgetown University, 20007 - Washington/US
  • 2 Internal Medicine Department, Hematology Division, KBC - University Hospital Centre Zagreb, 10000 - Zagreb/HR
  • 3 Internal Medicine, MedStar Georgetown University Hospital, 20007 - Washington/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 891MO

Background

FL is biologically and clinically heterogeneous with wide variations in outcomes. Progression of disease within 24 months after treatment (POD24) predicts overall survival (OS) in patients (pts) treated with rituximab-based therapy. Pts with POD24 have a < 50% long-term survival. Identifying predictors of POD24 at outset is an area of unmet need. Total metabolic tumor volume (TMTV) is an independent predictor of outcomes in FL. However, TMTV calculations are not routinely available, unlike SUVmax. Thus, we aimed at determining the correlation of baseline SUVmax with POD24 in FL.

Methods

We performed a retrospective chart review of pts with newly diagnosed FL from January 2011-January 2019. Comparison of PFS was done with log-rank test and multivariate analysis was conducted with Cox regression.

Results

100 pts with median age 60 years (29-86 years) were included. Baseline characteristics are mentioned in the attached figure. 21% of pts relapsed within 24 months (POD24) however median OS was unable to be calculated due to insufficient OS events. Baseline PET-CT analysis showed median SUV max value of 8.55 (0-38.9). No difference in correlation was noted between baseline SUVmax and initial laboratory data collected (ANC, ALC, Hgb, Plt, LDH, albumin, and globulin). Median SUV max for POD24 pts was higher at 9.19 vs 7.40 for non-POD24 however, comparison of SUVmax by POD24 status showed no statistically significant difference between the two groups (p=0.95). T-test also failed to note a difference between baseline laboratory variables and PET-CT determinates (number of nodal and extranodal sites) between POD24 and non-POD24 pts.

Conclusions

In our analysis, baseline SUVmax did not predict POD24 nor were there significant differences in the comparison of clinical variables between the two POD24 groups. Gene-expression profiling (GEP) scores have been developed to predict PFS in FL and high-risk signatures have been found to react differently to different chemotherapy backbones. Future research efforts should focus on increasing the feasibility and adoption of GEP in clinical practice, defining molecular subtypes of FL prior to treatment, and assigning therapy on the basis of those results.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.